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Arising from the city of Wuhan, Hubei province in China, a novel coronavirus named
severe acute respiratory syndrome coronavirus 2 has been rapidly spreading since its first
presentation in late 2019. The World Health Organization declared a pandemic on the
11th March 2020, and as of 29th of April 2020 more than 3 million cases have been
reported worldwide with over 225000 confirmed deaths. Where mechanical ventilation
may not be enough, extracorporeal membrane oxygenation (ECMO) could play a role as a
form of rescue therapy and may provide beneficial results in the hands of skilled clinicians
in centers with experience of using ECMO appropriately in selected patients. Our un-
derstanding of COVID‐19 is ever‐changing and the need for intensive care beds is rising,
which means that ECMO will surely play a key role in the near future.
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1 | INTRODUCTION
Arising from the city of Wuhan, Hubei province in China, a novel
coronavirus named severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2) has been rapidly spreading since its first presentation
in late 2019. The World Health Organization (WHO) declared a
pandemic on the 11th March 2020, and as of late April 2020 more
than 2.7 million cases have been reported worldwide. We are in
unprecedented times fighting a pathogen that is not fully understood.
Those who suffer from this illness may experience a clinical course
ranging from being asymptomatic to having a minor illness, and in a
significant minority a severe form of viral pneumonia, which can re-
sult in respiratory failure and death.
SARS‐CoV‐2 is an RNA virus and part of the family of
Coronaviruses and the third of its kind to affect humans in recent dec-
ades. It is thought to gain entry into type 2 pneumocytes via the ACE2
receptor, and the cytokine storm that is created in response to this virus
can result in acute respiratory distress syndrome (ARDS), which can
severely impair gas exchange.1 Where mechanical ventilation may not be
enough to provide sufficient oxygenation, extracorporeal membrane
oxygenation (ECMO) may play a role as a form of rescue therapy and
may provide beneficial results in the hands of skilled clinicians in centers
with experience of ECMO use in appropriately selected patients.2
2 | LITERATURE SEARCH METHOD
A comprehensive literature search is done through the available elec-
tronic database to identify articles that reported the use of ECMO and
mechanical circulatory support in COVID‐19 patients. The keywords
used were “mechanical circulatory,” “extra‐corporeal membrane oxyge-
nation,” “SARS‐CoV‐2,” “SARS‐CoV,” “ECMO,” “VA‐ECMO OR VV‐
ECMO” “COVID‐19” “mechanical support.” The search terms were used
as keywords and in combination as MeSH terms to maximize the output
from literature findings. References of each included article is cross‐
checked for any possible relevant study.
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The inclusion criteria were articles that discussed the indications,
outcomes, and survival benefit from using mechanical circulatory
support in the form of VV‐ECMO or VA‐ECMO in patients with
COVID‐19.
3 | WHEN SHOULD WE USE ECMO IN
COVID‐19 PATIENTS?
ECMO is a form of cardiopulmonary bypass and can be divided into
venovenous (VV‐ECMO) and venoarterial (VA‐ECMO), which can be
used in the setting of respiratory failure and cardiogenic shock, respec-
tively. VV‐ECMO can provide respiratory support and can replace the gas
exchange function of the lungs and minimize ventilator‐induced lung in-
jury, barotrauma, and oxygen toxicity. VA‐ECMO can provide both re-
spiratory and hemodynamic support and may be of use to COVID‐19
patients who sustain myocardial injury leading to refractory cardiogenic
shock.3 The WHO has provided guidelines on managing ARDS, which
focus on ventilation strategies that have proven to be useful in the setting
of ARDS in the past. They advise on using lower tidal volumes (4‐8mL/kg
predicted body weight), lower inspiratory pressure (plateau pressure
<30 cmH20), prone ventilation greater than 12 hours, and conservative
fluid management, and ECMO usage has been advised in expert
centers.4
Patient selection is crucial when considering ECMO and those
who are inappropriately selected stand a much lower chance of
survival. Extracorporeal Life Support Organization (ELSO) has pro-
vided selection criteria needed for ECMO referral. If in spite of op-
timal ventilation strategies, neuromuscular blockade, appropriate
PEEP, prone positioning, and the use of pulmonary vasodilators, pa-
tients develop the following criteria: PaO2/FiO2 less than 60mmHg
for greater than 6 hours, PaO2 /FiO2 less than 50mmHg less than
3 hours or pH less than 7.20 + PaCO2 greater than 80mmHg for less
than 6 hours, and do not have any contraindications, they may be
suitable for ECMO referral.5 They have set a list of relative and
absolute contraindications such as advanced age, multiorgan failure,
advanced lung disease, and severe acute neurological injury to name
a few (Table 1). The Murray score (Table 2) stratifies the severity of
acute lung injury and values of greater than 2 should be considered
for transfer to centers with ECMO facilities. Patients with ARDS and
a Murray score of 3 to 4 may be suitable candidates for ECMO.6
4 | EFFECT OF ECMO IN PREVIOUS
PANDEMICS
Alshahrani et al studied the effect of ECMO during the Middle Eastern
respiratory syndrome (MERS) outbreak. Patients suffering from MERS
had been known to develop ARDS. VV‐ECMO was offered to those who
failed optimal ventilation strategies and were found to have lower in‐
hospital mortality, better PaO2/FiO2 ratios, and fewer instances of organ
failure.7 The use of ECMO has also emerged during the H1N1 pandemic
and several studies have reported on their outcomes during that period.8
Noah et al9 found that mortality rates during the H1N1 pandemic of
2009 were almost twice as much in non‐ECMO patients when compared
with ECMO patients; 52.5% and 27.5%, respectively.
When considering ECMO a question of when to intervene arises:
in the setting of COVID‐19, would early use of ECMO be beneficial
or should patients be placed on mechanical ventilation first and then
transitioned to ECMO should they continue to deteriorate? There
may be two separate components to hypoxemic respiratory failure:
those with normal or high compliance, and those with low compliance
and severe hypoxia. ECMO may not be indicated until lung com-
pliance worsens or hypoxemia that is deemed to be severe sets in.10
Combes et al placed a group of patients with non‐COVID‐related
ARDS immediately on VV‐ECMO and found than after a period of
60 days there was no significant difference between the early application
of ECMO and the control group, which followed conventional treatment.
Twenty‐eight percent of their patients, however, needed to cross over to
the ECMO group for refractory hypoxemia.11
TABLE 1 Indications for ECMO use in COVID‐19
Indications (1) Hypoxic respiratory failure despite optimal ventilation strategies
(as per ELSO guidelines for ARDS)
(2) Severe hypercapnia (pH <7.2 and PaCO2 >80 mmHg for >6 h)
(3) Prolonged ventilation <7 d
(4) Cardiogenic shock (refractory to conventional therapy—cardiac index
<2 L/min/m2, central venous oxygen saturation ScVO2 <65%)
(5) Murray score >3
(6) Single organ failure with minimal or no comorbidities
Contraindications (1) Disseminated malignancy
(2) Significant brain injury
(3) Irreversible cardiac or pulmonary disease
(4) Current intracranial hemorrhage
(5) Severe or multiple comorbidities
(6) Multiorgan failure
(7) Immunocompromised status
(8) Advanced age (relative contraindication)
(9) Prolonged cardiopulmonary resuscitation >60min before starting ECMO
Note: ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; ELSO, extracorporeal life support organization.
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5 | CURRENT EVIDENCE AND OUTCOMES
OF ECMO
Our understanding of COVID‐19 is evolving and the role of ECMO is
being studied at various specialist centers. These centers tend to
save ECMO for those who are critically ill. Yang et al studied 52
critically ill patients and six of these patients were placed on ECMO.
Sixty‐seven percent of these patients had ARDS and of the six on
ECMO only one had survived beyond the 28‐day period. PaO2/FiO2
ratio was shown to differ between survivors and nonsurvivors being
100 mmHg and 62.5 mmHg, respectively, indicating the severity of
the disease and prognosis.12 Li et al placed eight out of 16 of their
COVID‐19 patients on ECMO. Of these four had died (50%) and
three were weaned off ECMO but were still on mechanical ventila-
tion (37.5%). Only one patient had been weaned off ECMO before
the 28‐day mark.6 Zhan et al reported a case of a low‐risk individual
who was placed on ECMO therapy within hours of intubation, the
clinicians realising early on that mechanical ventilation was in-
sufficient. This patient eventually recovered and was discharged
within 40 days of initial presentation.13
Henry et al reviewed 234 cases of COVID‐19‐related ARDS in
China of which 17 (7.25%) received ECMO. The study showed a 94.1%
mortality rate in ECMO patients compared with 70.9% in conventional
patients, though the severity of ARDS and the timing of ECMO in-
tervention is not mentioned, bearing in mind that those who are most
ill are more likely to be provided with ECMO.14 Zeng et al15 placed
12 COVID patients on ECMO following hypoxemic respiratory failure
despite conventional therapy, four of which have died, and three have
been weaned off ECMO and improving. Bemtgen et al presented a
COVID‐19 patient with cardiovascular disease and a recent myo-
cardial infarction who was placed on VA‐ECMO and a percutaneous
ventricular assist device. The patient developed ARDS, cardiogenic and
vasoplegic shock. By day 7 VA was switched to VV‐ECMO and the
patient continued to be on ECMO as the ARDS persisted, indicated a
role for VA‐ECMO in selected cases, and the persistence and pro-
gression of ARDS in COVID‐19 underlining its prognostic value.16
Jacobs et al performed a multicenter study involving nine hospitals of
the 32 patients that were placed on ECMO. They found 17 patients to
be still on ECMO and five survivors successfully decannulated. The
average time period from intubation to decannulation was 4 days, and
poorer outcomes were seen in patients on VA‐ECMO. Only one out of
the 10 who were nonsurvivors suffered cerebral bleeding while on
ECMO.17
Lung compliance may provide us with a useful parameter to guide
us in the use of ECMO. Zochios et al state that in COVID‐related
hypoxemic respiratory failure, patients can be divided into those with
normal or high lung compliance and those with low lung compliance.
ECMO is deemed to be suitable to those who have had prolonged
mechanical ventilation (<7 days), worsening lung compliance, and
failed conventional strategies.9 There have been cases reported of
COVID‐19 patients presenting with concomitant pulmonary embolism
(PE) and if undiagnosed it may lead to higher mortality rates despite
optimal ventilation techniques.18
6 | COMPLICATIONS
Complications can arise from the use of ECMO with hemorrhage and
coagulopathy being the most common. Hemorrhage can range from
cannula site to intracranial and pulmonary bleeding. These patients
are also at risk of thromboembolism paradoxically due to prolonged
bed rest, comorbidities, and disease burden. DVT and PE have been
identified while patients have been on ECMO. COVID‐19 has been
shown to promote thrombosis and in severe cases can result in dis-
seminated intravascular coagulation, which combined with ECMO
will place the patient at greater risk of coagulopathy.19,20 Mechanical
complications though less likely can still occur such as oxygenator
and cannula failure. Infection either from cannula sites or nosocomial
infections should also be considered and may result in a super-
imposed infection along with COVID‐19.21
7 | CONCLUSION
ECMO should be reserved for those who are critically ill and in these
current times with the emergence of COVID‐19 we are seeing more
and more critically ill patients. ECMO is resource‐intensive and re-
quires clinical knowledge, understanding, and experience of ECMO to
obtain the best results. There are few intensive care beds and even
fewer ECMO machines and it is imperative that patients are selected
TABLE 2 Murray score for acute lung injury
Parameter/score 0 1 2 3 4
PaO2/
FiO2 (mmHg)
>300 225‐299 175‐224 100‐174 <100
CXR Normal Alveolar consolidation
confined to 1 quadrant
Alveolar consolidation
confined to 2 quadrants
Alveolar consolidation
confined to 3 quadrants
Alveolar consolidation
confined to 4 quadrants
PEEP <5 6‐8 9‐11 12‐14 >15
Compliance
(mL/cmH2O)
>80 60‐79 40‐59 20‐39 <19
Note: The final score is calculated by the addition of the component parts. Score: 0, no lung injury; 1‐2.5, mild to moderate lung injury; and >2.5, severe
lung injury.
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correctly. ELSO has provided guidance on the criteria needed to refer
these patients for ECMO and what cohort of patients should be
deemed unsuitable for ECMO. Timing may play an important factor.
Should these patients be provided ECMO immediately or soon after
presentation, or should maximal ventilation strategies be trialed
before ECMO is utilized as a last resort? ELSO currently recommend
the latter. Previous viral illnesses in recent times such as MERS and
H1N1 have shown to present good results from ECMO. There may
be scope for the use of ECMO as rescue therapy and this interven-
tion should, therefore, be strongly considered in patients with severe
lung injury secondary to COVID‐19.
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